Arrowhead reports fiscal Q3 2026 results with plozasiran Phase 3 data and Madrigal deal
Arrowhead reported topline Phase 3 results for plozasiran in severe hypertriglyceridemia and disclosed a PNPLA3 licensing deal with Madrigal worth up to $975 million in milestones.
Arrowhead Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2026, alongside a series of pipeline and regulatory updates.
The company reported topline data for the global Phase 3 "SHASTA-3" and "SHASTA-4" clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG)1, with full results to be presented at the European Society of Cardiology Congress on August 30, 2026, according to the release. Both studies met the primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints1. Median triglyceride reductions were 79% and 81% from baseline in SHASTA-3 and SHASTA-4, respectively1. The company also reported a statistically significant 78% reduction in acute pancreatitis events versus placebo across the sHTG population, with a 100% event reduction in patients with triglycerides above 880 mg/dL and prior pancreatitis history1.
Arrowhead said it acquired an FDA priority review voucher that it plans to pair with a forthcoming supplemental NDA for plozasiran, expected to be filed by the end of 2026, aimed at expanding the approved indication to include sHTG1.
On the pipeline side, the company completed enrollment in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, after raising the enrollment target from 60 to 70 patients due to demand1, with completion anticipated in mid-20271.
Arrowhead also announced a licensing deal for ARO-PNPLA3 with Madrigal Pharmaceuticals in MASH. Under the agreement, Madrigal paid $25 million upfront, with Arrowhead eligible for up to $975 million in development, regulatory, and sales milestones plus tiered royalties from high-single digits to mid-teens1.
Financially, revenue was $75,253 thousand versus $27,767 thousand a year earlier, with a net loss attributable to Arrowhead of $(194,280) thousand1. Total cash resources stood at $1,566,886 thousand as of June 30, 2026, up from $781,524 thousand at fiscal year-end 20251.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.